NEW DELHI: Biocon on Thursday reported a 95 per cent decrease in its consolidated net profit at Rs 31 crore in the June quarter. The Bengaluru-based firm posted a net profit of Rs 660 crore in the April-June quarter of the last fiscal. Total revenue declined to Rs 4,022 crore in the June quarter as against Rs 4,567 crore in the year-ago period, Biocon Ltd said in a statement. “Biocon opened FY26 with a strong performance, driven by continued gains in Biosimilars and CRDMO, and a steady showing in Generics,” Kiran Mazumdar-Shaw, Chairperson, Biocon Group, stated. Operating revenue rose 15 per cent YoY to Rs 3,942 crore, with EBITDA up 19 per cent on a like-for-like basis, demonstrating operating leverage and the robustness of businesses, she added. “The recent QIP has strengthened our balance sheet and enabled us to increase our ownership in Biocon Biologics by facilitating the exit of structured equity investors, aligning capital structure with long-term strategic priorities,” Mazumdar-Shaw said. With execution momentum across all businesses and expanded capacity through acquisitions in the US by Syngene and Biocon Generics, the company is well-positioned to drive long-term value creation in FY26 and beyond, she added.